艾司氯胺酮治疗重性抑郁、产后抑郁及围术期抑郁的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入67项随机对照试验共11553名参与者,评估艾司氯胺酮治疗重性抑郁障碍/难治性抑郁、预防产后抑郁及术后抑郁的疗效与安全性。结果显示艾司氯胺酮在治疗与预防抑郁方面均有效,静脉给药效果最佳,但头晕发生率更高。
要点
- 艾司氯胺酮治疗重性抑郁/难治性抑郁、预防产后6周及术后3个月抑郁均有效。
- 静脉给药在治疗重性抑郁/难治性抑郁及预防产后抑郁方面效果最大。
- 治疗与预防用途中头晕发生率均更高。
核心结论
- 艾司氯胺酮对重性抑郁/难治性抑郁的治疗及产后抑郁、术后抑郁的预防均显示短期和长期疗效,且疗效因给药途径而异。
研究设计与样本
- 系统综述与荟萃分析,检索Pubmed、MEDLINE、Embase、Web of science和Cochrane Library至2025年7月24日。
- 纳入67项随机对照试验共11553名参与者:19项重性抑郁/难治性抑郁、18项产后抑郁、30项术后抑郁。
- 效应量采用固定或随机效应模型估计标准化均数差(SMD)与相对危险度(RR)及95%CI,并用累积排序曲线下面积对给药方案排序。
主要发现
- 与对照相比,重性抑郁/难治性抑郁的合并SMD为-0.36(95%CI -0.49, -0.24)。
- 产后6周产后抑郁的SMD为-0.40(95%CI -0.78, -0.02)。
- 术后3个月术后抑郁的SMD为-0.82(95%CI -1.46, -0.18)。
- 静脉给药在治疗重性抑郁/难治性抑郁和预防产后抑郁方面效果最大,不受结局指标类型影响。
- 艾司氯胺酮在治疗和预防用途中均与更高的头晕发生率相关。
关键数值与推荐
- 疗效结局包括抑郁量表评分、缓解率、应答率及抑郁发生率;安全性结局包括出现于两项以上比较中的不良事件。
- 报告了重性抑郁/难治性抑郁、产后6周产后抑郁及术后3个月术后抑郁的合并SMD及95%CI。
临床怎么用
- 艾司氯胺酮可用于重性抑郁/难治性抑郁的治疗及产后抑郁、术后抑郁的预防,选择给药途径时需权衡疗效与头晕风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review and meta-analysis aimed to evaluate esketamine in managing major depressive disorder (MDD) / treatment resistant depression (TRD), preventing postpartum depression (PPD) and postoperative depression, including comparisons within and between administrations. Five databases (Pubmed, MEDLINE, Embase, Web of science and the Cochrane Library) were searched up to July 24, 2025. Randomized clinical trials investigating esketamine for depression, compared with control group were included. Efficacy outcomes included depression scales, remission rate, response rate and depression incidence rates. Safety outcomes included adverse events reported in more than two comparisons. Standardized mean differences (SMDs) and Relative risks (RRs) with their corresponding 95% confidential intervals (CIs) were estimated using fixed- or random-effects models. Administration regimes were ranked using surface under the cumulative ranking. Of 12,285 studies identified, 67 trials with 11,553 participants were included: 19 trials on MDD/TRD, 18 studies on PPD and 30 studies on postoperative depression. The overall pooled SMDs, compared with comparator, showed effective in treating and preventing depression (MDD -0.36, 95%CI -0.49, -0.24; PPD for postpartum 6 week -0.40, 95%CI -0.78, -0.02, and postoperative depression for postoperative 3 month -0.82, 95%CI -1.46, -0.18). Intravenous administration yields the greatest effect in treating MDD/TRD and preventing PPD, no matter of the measured outcome (scales scores, response rate of MDD/TRD or incidence rate of PPD or postoperative depression). Esketamine was associated with higher incidences of dizziness in both therapeutic and preventive effects. These findings highlight both short- and long-term efficacy of eskatemine in treating MDD/TRD, and preventing PPD and postoperative depression, with efficacy differing across administration routes.
引用
- Huang C, Hu L, Liu W, et al. Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis. Mol Psychiatry. 2025. PMID: 41152407. doi:10.1038/s41380-025-03320-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。